Suchergebnisse
Amdocs (DOX) Q3 Earnings Match Estimates
Amdocs (DOX) came out with quarterly earnings of $1.84 per share, in line with the Zacks Consensus Estimate . This compares to earnings of $1.72 per share a year ago. These figures are adjusted for
Biodesix, Inc. (BDSX) Reports Q2 Loss, Beats Revenue Estimates
Biodesix, Inc. (BDSX) came out with a quarterly loss of $0.71 per share versus the Zacks Consensus Estimate of a loss of $0.86. This compares to a loss of $1.6 per share a year ago. These figures
Corpay (CPAY) Q2 Earnings and Revenues Beat Estimates
Corpay (CPAY) came out with quarterly earnings of $7 per share, beating the Zacks Consensus Estimate of $6.6 per share. This compares to earnings of $5.13 per share a year ago. These figures are
Clearfield (CLFD) Beats Q3 Earnings Estimates
Clearfield (CLFD) came out with quarterly earnings of $0.22 per share, beating the Zacks Consensus Estimate of $0.2 per share. This compares to earnings of $0.11 per share a year ago. These figures
Central Garden (CENTA) Tops Q3 Earnings and Revenue Estimates
Central Garden (CENTA) came out with quarterly earnings of $1.54 per share, beating the Zacks Consensus Estimate of $1.51 per share. This compares to earnings of $1.56 per share a year ago. These
Central Garden (CENT) Surpasses Q3 Earnings and Revenue Estimates
Central Garden (CENT) came out with quarterly earnings of $1.54 per share, beating the Zacks Consensus Estimate of $1.51 per share. This compares to earnings of $1.56 per share a year ago. These
AppLovin (APP) Tops Q2 Earnings Estimates
AppLovin (APP) came out with quarterly earnings of $3.76 per share, beating the Zacks Consensus Estimate of $3.72 per share. This compares to earnings of $2.26 per share a year ago. These figures
Axon Enterprise (AXON) Q2 Earnings Miss Estimates
Axon Enterprise (AXON) came out with quarterly earnings of $1.88 per share, missing the Zacks Consensus Estimate of $1.89 per share. This compares to earnings of $2.12 per share a year ago. These
Arcutis Biotherapeutics, Inc. (ARQT) Q2 Earnings and Revenues Surpass Estimates
Arcutis Biotherapeutics, Inc. (ARQT) came out with quarterly earnings of $0.11 per share, beating the Zacks Consensus Estimate of $0.09 per share. This compares to a loss of $0.13 per share a year
Vanda Pharmaceuticals (VNDA) Reports Q2 Loss, Lags Revenue Estimates
Vanda Pharmaceuticals (VNDA) came out with a quarterly loss of $1.04 per share versus the Zacks Consensus Estimate of a loss of $0.51. This compares to a loss of $0.46 per share a year ago. These
Curaleaf Holdings, Inc. (CURLF) Q2 Earnings and Revenues Surpass Estimates
Curaleaf Holdings, Inc. (CURLF) came out with quarterly earnings of $0.05 per share, beating the Zacks Consensus Estimate of a loss of $0.2 per share. This compares to a loss of $0.18 per share a
Cirrus Logic (CRUS) Q1 Earnings Surpass Estimates
Cirrus Logic (CRUS) came out with quarterly earnings of $1.84 per share, beating the Zacks Consensus Estimate of $1.8 per share. This compares to earnings of $1.51 per share a year ago. These
Barrett Business Services Q2 Earnings Call Highlights
Key Points
- Interested in Barrett Business Services, Inc.? Here are five stocks we like better.
- Q2 growth was modest: Gross billings rose 2.6% year over year to $2.29 billion, while diluted EPS
Amtech Systems Q3 Earnings Call Highlights
Key Points
- Interested in Amtech Systems, Inc.? Here are five stocks we like better.
- Strong AI-driven growth: Fiscal Q3 revenue rose 14% year over year to $22.4 million, while Thermal Processing
Arcutis Biotherapeutics Q2 Earnings Call Highlights
Key Points
- Interested in Arcutis Biotherapeutics, Inc.? Here are five stocks we like better.
- Strong financial performance: Arcutis reported Q2 2026 net product revenue of $129.9 million, up 59%
AppLovin Q2 Earnings Call Highlights
Key Points
- Interested in AppLovin Corporation? Here are five stocks we like better.
- Second-quarter results fell below guidance: Revenue rose 53% year over year to $1.92 billion and adjusted
Alto Ingredients Q2 Earnings Call Highlights
Key Points
- Interested in Alto Ingredients, Inc.? Here are five stocks we like better.
- Alto Ingredients reported its fourth consecutive quarter of profitability, with second-quarter net sales
Akebia Therapeutics Q2 Earnings Call Highlights
Key Points
- Interested in Akebia Therapeutics, Inc.? Here are five stocks we like better.
- Vafseo revenue rose sharply to $21.3 million in Q2 2026, up 34% sequentially and 60% year over year
Airgain Q2 Earnings Call Highlights
Key Points
- Interested in Airgain, Inc.? Here are five stocks we like better.
- Second-quarter revenue rose to $13.7 million, up 19% sequentially, while adjusted EBITDA turned positive at
ADMA Biologics Q2 Earnings Call Highlights
Key Points
- Interested in ADMA Biologics Inc? Here are five stocks we like better.
- Second-quarter revenue rose 2% to $124.4 million, driven by a 24% increase in ASCENIV sales to $102.9 million


